Floatz logo

m1231

Esophageal Cancer

EMD Serono Research & Development Institute, Inc.Phase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

131 Active assets in the Esophageal Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 4BB
Benadryl
Ciusss de L'Est de l'Île de Montréal
Phase 3B
Cyclophosphamide
Sutro Biopharma, Inc.
Phase 3B
Epirubicin
Sutro Biopharma, Inc.
Phase 3B

View all 50 →

Same molecule, other indications

m1231 is also rated in:

metastatic malignant neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →